Entering text into the input field will update the search result below

ChromaDex Corporation (CDXC) CEO Rob Fried on Q2 2021 Results - Earnings Call Transcript

SA Transcripts profile picture
SA Transcripts

ChromaDex Corporation (NASDAQ:CDXC) Q2 2021 Earnings Conference Call August 3, 2021 4:30 PM ET

Company Participants

Brianna Gerber - Investor Relations

Rob Fried - Chief Executive Officer

Kevin Farr - Chief Financial Officer

Frank Jaksch - Founder and Executive Chairman

Conference Call Participants

Brian Nagel - Oppenheimer

Jeffrey Cohen - Ladenburg

Raghuram Selvaraju - H.C. Wainwright

Jeff Van Sinderen - B. Riley

Mitch Pinheiro - Sturdivant

JP Mark - Farmhouse Equity


Ladies and gentlemen, thank you for standing by and welcome to ChromaDex Corporation’s Second Quarter 2021 Earnings Conference Call. My name is Ashley and I will be the conference operator today. At this time, all participants are in a listen-only mode. And as a reminder, this conference call is being recorded. This afternoon, ChromaDex issued a news release announcing the company’s financial results for the second quarter of 2021. If you have not reviewed this information, both are available within the Investor Relations section at ChromaDex’s website at www.chromadex.com.

I would now like to turn the conference call over to Brianna Gerber, Vice President of Finance and Investor Relations. Please go ahead Ms. Gerber.

Brianna Gerber

Thank you. Good afternoon and welcome to ChromaDex Corporation second quarter 2021 results investor call. With us today are ChromaDex’s Chief Executive Officer, Rob Fried; Founder and Executive Chairman, Frank Jaksch; and Chief Financial Officer Kevin Farr.

Today’s conference may include forward-looking statements, including statements related to ChromaDex’s research and development and clinical trial plans, and the timing and results of such trials, the timing of future regulatory filings, the expansion of the sale of Tru Niagen in new markets, business opportunities, future financial results, cash needs, operating performance, investor interest and business prospects and opportunities as well as anticipated results of operation. Forward-looking statements represent only the company’s estimates on the date of this conference call and are not intended to

Recommended For You

Comments (7)

Review paper on NR vs. coronavirus:

petenj profile picture
Company is at significant risk beginning in 2H. Unless they win their legal battle, this becomes a smoldering fire. They will have brutal unload following the WalMart ship-to/load-in, that will occur Q3 and also Q4. Heavy legal expenses COMBINED WITH the start of a TV media program will be severely onerous. TV advertising almost bankrupted the company years ago, and could do it once again. They don't have the critical mass to support an impactful TV campaign....and the WalMart shopper, needless to say, is not the consumer target for TruNiagen. The company's future rides on the CMO. Good luck buddy.
CR144 Research profile picture
@petenj A lot depends on the outcome of the court case with Elysium. If they win the share price will take off to $20+. If they lose the share price may collapse to $3.
Robbe Delaet profile picture
@petenj Chromadex became much more professional lately, partially due to the major investment by Li Ka Shing, one of the brightest investors in human history. Don't expect them to make big mistakes. Looking forward to the accelerating growth they talked about during the cc.
@petenj true, "TV" is useless in 2021 (what is a TV? Who watches "commercials"? Not any demographic smart enough to care about their health...)

CDXC needs reporting from independent media, YouTube fitness gurus, doctors, and other sources that people actually use for health.
CR144 Research profile picture
"However, we expect that our third quarter total net sales will be flat to slightly down from the second quarter"
CR144 Research profile picture
"Total legal expense was down compared to last quarter, but remains high as we prepare for three trials this year."
To report an error in this transcript, .Contact us to add your company to our coverage or use transcripts in your business. Learn more about Seeking Alpha transcripts here. Your feedback matters to us!
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.